We generated a unique panel of isogenic cell models with the following genotypes via CRISPR-Cas9 engineering: Rpl5+/-, Rpl10 R98S, Rpl11+/-, Rpl22+/-, Rpl22-/-, Rps15 P131S and Rps15 H137Y. As cellular background, we chose for Ba/F3 cells. These are mouse lymphoid pro-B-cells, offering a relevant cellular background as most of these mutations have been linked to lymphoid malignancies as T-ALL and CLL. Quantitative proteomics profiling of this isogenic cell line panel shed a light on the molecular biology underlying the oncogenic mechanisms of these ribosomal lesions.